Cargando...
Developing pharmacological therapies for Alzheimer disease
Alzheimer disease (AD), while chronic and progressive with an average progression of 7–10 years, is both multifactorial and heterogeneous. Thus, AD offers a large window of opportunity and a large number of therapeutic targets to inhibit it. The selection of a therapeutic target, however, is one of...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2007
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3139452/ https://ncbi.nlm.nih.gov/pubmed/17604997 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00018-007-7221-9 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|